Literature DB >> 11160222

Constitutive association of SHP-1 with leukocyte-associated Ig-like receptor-1 in human T cells.

J G Sathish1, K G Johnson, K J Fuller, F G LeRoy, L Meyaard, M J Sims, R J Matthews.   

Abstract

The intracellular Src homology 2 (SH2) domain-containing protein tyrosine phosphatase (SHP-1) is a negative regulator of cell signaling and contributes to the establishment of TCR signaling thresholds in both developing and mature T lymphocytes. Although there is much functional data implicating SHP-1 as a regulator of TCR signaling, the molecular basis for SHP-1 activation in T lymphocytes is poorly defined. A modification of the yeast two-hybrid system was employed to identify in T cells phosphotyrosine-containing proteins capable of binding the SH2 domains of SHP-1. From this yeast tri-hybrid screen, the p85beta subunit of phosphatidylinositol 3-kinase and the immunoreceptor tyrosine-based inhibitory motif-containing receptors, leukocyte-associated Ig-like receptor-1 (LAIR-1) and programmed death-1 (PD-1), were identified. Coimmunoprecipitation studies demonstrated that the exclusive phosphotyrosine-containing protein associated with SHP-1 in Jurkat T cells under physiological conditions is LAIR-1. Significantly, this interaction is constitutive and was detected only in the membrane-enriched fraction of cell lysates. Ligand engagement of the SH2 domains of SHP-1 is a prerequisite to activation of the enzyme, and, consistent with an association with LAIR-1, SHP-1 was found to be constitutively active in unstimulated Jurkat T cells. Importantly, a constitutive interaction between LAIR-1 and SHP-1 was also detected in human primary T cells. These results illustrate the sustained recruitment and activation of SHP-1 at the plasma membrane of resting human T cells by an inhibitory receptor. We propose that this mechanism may exert a constitutive negative regulatory role upon T cell signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160222     DOI: 10.4049/jimmunol.166.3.1763

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  The p85 subunit of phosphoinositide 3-kinase is associated with beta-catenin in the cadherin-based adhesion complex.

Authors:  R J Woodfield; M N Hodgkin; N Akhtar; M A Morse; K J Fuller; K Saqib; N T Thompson; M J Wakelam
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

Review 2.  PD-1 signaling in primary T cells.

Authors:  James L Riley
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 3.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 4.  Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-08-16       Impact factor: 4.481

5.  Differential gene expression levels might explain association of LAIR2 polymorphisms with pemphigus.

Authors:  Carolina Maciel Camargo; Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-12-31       Impact factor: 4.132

6.  Identification and characterization of the rat homologue of LAIR-1.

Authors:  Robert Jan Lebbink; Talitha de Ruiter; Guido J A Kaptijn; Linde Meyaard
Journal:  Immunogenetics       Date:  2005-05-18       Impact factor: 2.846

Review 7.  SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.

Authors:  Ulrike Lorenz
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Leucocyte-associated immunoglobulin-like receptor-1 is an inhibitory regulator of contact hypersensitivity.

Authors:  Ryusuke Omiya; Fumihiko Tsushima; Hidehiko Narazaki; Yukimi Sakoda; Atsuo Kuramasu; Youn Kim; Haiying Xu; Hideto Tamura; Gefeng Zhu; Lieping Chen; Koji Tamada
Journal:  Immunology       Date:  2009-12       Impact factor: 7.397

Review 9.  Negative signaling by inhibitory receptors: the NK cell paradigm.

Authors:  Eric O Long
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

Review 10.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.